After the U.S. withdrew from the World Health Organization, it wasn't clear they would participate in this WHO-led meeting to ...

In a sudden reversal, the U.S. Food and Drug Administration (FDA) has agreed to review Moderna’s experimental mRNA influenza vaccine.

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...

Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults after all.

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Feb ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...

The FDA will review Moderna’s new mRNA flu vaccine after reversing course, raising fresh concerns about potential setbacks ...